.jpg)
Covaxin, the vaccine developed by the government's medical research agency and Bharat Biotech, was found to have a 77.8 per cent efficacy rate against symptomatic COVID-19 in a long-awaited analysis published in The Lancet.
The study also found it to be 65.2 per cent effective against the more dangerous Delta variant of the coronavirus in its preliminary analysis but said further investigations are necessary to confirm it.
Covaxin, which uses traditional, inactivated-virus technology, "induces a robust antibody response" two weeks after two doses are given, The Lancet said in a statement
